Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Changes in Serum Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1–34)

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Therapeutic Effect of Rhpth (1-34) on Glucocorticoid-Induced Osteoporosis in Rats

Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.

Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Osteoporosis of Ovariectomized Rats

Vitamin D supplementation in primary hyperparathyroidism: effects on 1,25(OH)2 vitamin D and FGF23 levels

PTH[1-34] Improves the Effects of Core Decompression in Early-Stage Steroid-Associated Osteonecrosis Model by Enhancing Bone Repair and Revascularization

Molecular Mechanisms of Rhpth(1-34) Influence on Osteoporosis in Ovariectomized Rats

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

Intermittently Administered Parathyroid Hormone [1–34] Promotes Tendon-Bone Healing in a Rat Model

The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34)

Effects of PTH glandular and external dosing patterns on bone cell activity using a two-state receptor model—Implications for bone disease progression and treatment

Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis

Intermittent low-dose administration of recombinant human parathyroid hormone (1-34) promotes the expression of Osterix during early stage of fracture healing

[Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis]

PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis

PTHG2 Reduces Bone Loss in Ovariectomized Mice by Directing Bone Marrow Mesenchymal Stem Cell Fate

Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone

Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism

The effect of 1,25(OH)_2D_3 on bone metabolism in primary glomerulonephritis patients receiving glucocorticoid treatment

Short Cyclic Regimen With Parathyroid Hormone ( PTH ) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats